MX2016016836A - Metodos y dispositivos para tratar trastornos oculares posteriores. - Google Patents

Metodos y dispositivos para tratar trastornos oculares posteriores.

Info

Publication number
MX2016016836A
MX2016016836A MX2016016836A MX2016016836A MX2016016836A MX 2016016836 A MX2016016836 A MX 2016016836A MX 2016016836 A MX2016016836 A MX 2016016836A MX 2016016836 A MX2016016836 A MX 2016016836A MX 2016016836 A MX2016016836 A MX 2016016836A
Authority
MX
Mexico
Prior art keywords
end portion
devices
medicament container
methods
medicament
Prior art date
Application number
MX2016016836A
Other languages
English (en)
Inventor
White Daniel
Noronha Glenn
Victor Andino Rafael
John Brooks Christopher
Patel Samirkumar
Original Assignee
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearside Biomedical Inc filed Critical Clearside Biomedical Inc
Publication of MX2016016836A publication Critical patent/MX2016016836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Abstract

La presente invención se refiere a métodos y dispositivos para tratar uveítis, edema macular asociado con uveities y edema macular asociado con oclusión de vena retinal en un sujeto humano en necesidad del mismo. En ciertos aspectos, los dispositivos proporcionados en la presente incluyen un recipiente de medicamento que define un lumen configurado para contener un medicamento, una porción de extremo distal del recipiente de medicamento que incluye una porción de acoplamiento configurada para que se acople de forma removible a un montaje de aguja, una porción de extremo proximal del recipiente de medicamenteo que incluye una pestaña y un resalto longitudinal; un montaje de pistón que incluye una porción de extremo distal colocada de forma movible dentro del lumen del recipiente de medicamento; y un mango acoplado a una porción de extremo proximal del montaje de pistón.
MX2016016836A 2014-06-17 2015-06-17 Metodos y dispositivos para tratar trastornos oculares posteriores. MX2016016836A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462013209P 2014-06-17 2014-06-17
US201462018148P 2014-06-27 2014-06-27
US201462063792P 2014-10-14 2014-10-14
US201562155367P 2015-04-30 2015-04-30
US201562156802P 2015-05-04 2015-05-04
PCT/US2015/036299 WO2015195842A1 (en) 2014-06-17 2015-06-17 Methods and devices for treating posterior ocular disorders

Publications (1)

Publication Number Publication Date
MX2016016836A true MX2016016836A (es) 2017-07-27

Family

ID=54936084

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016836A MX2016016836A (es) 2014-06-17 2015-06-17 Metodos y dispositivos para tratar trastornos oculares posteriores.

Country Status (12)

Country Link
US (1) US20180042765A1 (es)
EP (1) EP3157463A4 (es)
JP (2) JP6774340B2 (es)
KR (1) KR102511477B1 (es)
CN (1) CN107072765A (es)
AU (1) AU2015277133A1 (es)
BR (1) BR112016029864A2 (es)
CA (1) CA2952822A1 (es)
IL (1) IL249602A0 (es)
MX (1) MX2016016836A (es)
RU (1) RU2017101236A (es)
WO (1) WO2015195842A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
EP3520749A1 (en) 2010-10-15 2019-08-07 Clearside Biomedical, Inc. Device for ocular access
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
WO2014179698A2 (en) 2013-05-03 2014-11-06 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US10226379B2 (en) 2014-02-12 2019-03-12 Orbit Biomedical Limited Method and apparatus for subretinal administration of therapeutic agent
US9925088B2 (en) 2014-06-06 2018-03-27 Janssen Biotech, Inc. Sub-retinal tangential needle catheter guide and introducer
US9949874B2 (en) 2014-06-06 2018-04-24 Janssen Biotech, Inc. Therapeutic agent delivery device with convergent lumen
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10219936B2 (en) 2014-09-11 2019-03-05 Orbit Biomedical Limited Therapeutic agent delivery device with advanceable cannula and needle
US10258502B2 (en) 2014-09-18 2019-04-16 Orbit Biomedical Limited Therapeutic agent delivery device
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017120601A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
US10399713B2 (en) 2016-01-19 2019-09-03 Dr. Py Institute Llc Devices and methods for formulation processing
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
US10478553B2 (en) 2016-03-09 2019-11-19 Orbit Biomedical Limited Apparatus for subretinal administration of therapeutic agent via a curved needle
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US11000410B2 (en) 2016-06-17 2021-05-11 Gyroscope Therapeutics Limited Guide apparatus for tangential entry into suprachoroidal space
US10806629B2 (en) 2016-06-17 2020-10-20 Gyroscope Therapeutics Limited Injection device for subretinal delivery of therapeutic agent
US10646374B2 (en) 2016-06-17 2020-05-12 Orbit Biomedical Limited Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
US11273072B2 (en) 2017-01-13 2022-03-15 Gyroscope Therapeutics Limited Suprachoroidal injection device
US11076984B2 (en) 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
WO2019133690A1 (en) * 2017-12-28 2019-07-04 Nichiban Co., Ltd. Transdermal drug delivery system and method for using same
US11724941B2 (en) 2018-02-15 2023-08-15 North Carolina State University Synthesis of micron and nanoscale carbon spheres and structures using hydrothemal carbonization
US20210046002A1 (en) * 2018-03-05 2021-02-18 Massachusetts Eye And Ear Infirmary Amelioration of autoimmune uveitis through blockade of csf1r
US20210236336A1 (en) * 2018-05-09 2021-08-05 North Carolina State University Applicator for corneal therapeutics
US11039954B2 (en) * 2019-03-21 2021-06-22 Microoptx Inc. Implantable ocular drug delivery devices and methods
CN110009626A (zh) * 2019-04-11 2019-07-12 北京百度网讯科技有限公司 用于生成图像的方法和装置
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
US20230089914A1 (en) * 2020-02-19 2023-03-23 Clearside Biomedical, Inc. Compositions comprising axitinib and methods of treating ocular disorders
EP4255569A1 (en) * 2020-12-02 2023-10-11 Telios Pharma, Inc. Methods and compositions for treating an ophthalmic condition
EP4262675A1 (en) * 2020-12-17 2023-10-25 Mobius Therapeutics, LLC Injection apparatus and method of use
CN113101502B (zh) * 2021-03-01 2023-01-17 李特 一种耳鼻喉科用治疗装置
CN113198003A (zh) * 2021-06-22 2021-08-03 万永年 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法
WO2023133455A1 (en) * 2022-01-06 2023-07-13 Clearside Biomedical, Inc. Compositions and methods for treating macular edema associated with uveitis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2951938B1 (ja) * 1998-03-19 1999-09-20 日本ケミカルリサーチ株式会社 薬剤溶解機構を内蔵した注射器
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
CA2553381C (en) * 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) * 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008070479A2 (en) * 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US8083759B2 (en) * 2007-11-02 2011-12-27 Refocus Ocular, Inc. Apparatuses and methods for forming incisions in ocular tissue
US8221353B2 (en) * 2008-10-21 2012-07-17 KMG Pharma, Inc Intravitreal injection device and system
US9033911B2 (en) * 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US20120101475A1 (en) * 2010-10-21 2012-04-26 Meridian Medical Technologies, Inc. High Efficiency Auto-Injector
EP2578260A1 (en) * 2011-10-07 2013-04-10 Sanofi-Aventis Deutschland GmbH Apparatus for intraocular injection
BR112015010566A2 (pt) * 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
WO2015095772A2 (en) * 2013-12-20 2015-06-25 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents

Also Published As

Publication number Publication date
KR102511477B1 (ko) 2023-03-16
EP3157463A1 (en) 2017-04-26
IL249602A0 (en) 2017-02-28
JP6774340B2 (ja) 2020-10-21
US20180042765A1 (en) 2018-02-15
KR20170039128A (ko) 2017-04-10
AU2015277133A1 (en) 2017-02-02
BR112016029864A2 (pt) 2017-08-22
CN107072765A (zh) 2017-08-18
JP2017524677A (ja) 2017-08-31
JP2020063236A (ja) 2020-04-23
CA2952822A1 (en) 2015-12-23
RU2017101236A3 (es) 2019-05-16
RU2017101236A (ru) 2018-07-17
EP3157463A4 (en) 2018-02-21
WO2015195842A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
MX2016016836A (es) Metodos y dispositivos para tratar trastornos oculares posteriores.
MX2018008469A (es) Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MX2016016070A (es) Introductor y guia de cateter con aguja tangencial subretinal.
MA40630A (fr) Dispositif d'administration d'un agent thérapeutique muni d'une canule et d'une aiguille pouvant avancer.
MY192241A (en) An injector docking device
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
NZ701069A (en) Methods and devices for drug delivery to ocular tissue using microneedle
MX360016B (es) Prenda de compresion medica terapeutica y metodo.
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
EA033212B1 (ru) Ланцетное устройство для лечения дерматологических расстройств и способ его применения
EP3405159A4 (en) TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASE BY PHOTOCOAGULATION
Hamilton et al. Stromal rejection in a deep anterior lamellar keratoplasty following influenza vaccination.
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2018001918A (es) Aplicación cuantitativa periorbital de farmacos oftalmologicos.
NZ729181A (en) Treatment of disease with poly-n-acetylglucosamine nanofibers
MX2017015664A (es) Administracion intravenosa de citrulina durante cirugia.
PL3128968T3 (pl) Strój do leczenia skórnych i podskórnych zaburzeń tkankowych oraz regeneracji sportowej, zawierający cylindryczny korpus
GB201210464D0 (en) Implantable medical device
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
MX351710B (es) Dispositivo auxiliar para el manejo de jeringas tipo carpule durante el procedimiento de anestesia odontológica.